ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the...
Neuroscience
Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive...
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare...
Neurophet to launch total solution for AD treatments ‘Neurophet AQUA AD’ at AAIC 2024
- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE...
New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12
Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and...
AAIC 2024: Linus Health to Unveil Groundbreaking Research at Leading Alzheimer’s Conference
Life sciences platform enhanced to make cognitive assessments easier and more precise BOSTON, July 24, 2024 /PRNewswire/ -- Linus Health, a...
Linus Health Acquires Together Senior Health to Expand its Platform to Better Serve Patients and Providers with End-to-End Workflow Capabilities
Company's virtual therapeutic programs and proprietary risk stratification algorithm support proactive detection of and intervention for cognitive decline BOSTON, July...
Holmusk and Veradigm Reach New Data Enrichment Milestone in Strategic Collaboration
Veradigm Network EHR data enables a deeper understanding of the patient journey and disorder progression NEW YORK and CHICAGO, July...
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
ViewMind Applauded by Frost & Sullivan for Revolutionizing Brain Health Assessment and Care with Its Ocular Digital Phenotyping Solution
ViewMind's Ocular Digital Phenotyping solution is a holistic approach to brain and mental health that builds trust through technology, enabling...
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm...
Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression
MORRISTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries...
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug Resistance
New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL /...
Aetna Policy Update Expands TMS Availability for Adolescents With Depression
Coverage criteria consistent with recent FDA clearance for NeuroStar TMSMALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
GlassView Taps Amazon Ads’ Stellantis US Agency & Enterprise Lead as VP, Client Partnerships
NEW YORK, July 19, 2024 /PRNewswire/ -- With a 20 year career in producing data-driven solutions for clients at Amazon...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic...
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up...
Venture-Backed The Way Launches First-of-Its-Kind Meditation Training App
Taught by renowned Zen Master and author Henry Shukman, new app offers program of long-term meditation training that guides users...
Cumulus Neuroscience to Present Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference
Full analysis of first-in-class CNS-101 study measuring functional neurophysiology at home in patients living with mild Alzheimer's dementiaPoster presentations scheduled for the...